Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 23, 2024 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and...
February 15, 2024 16:10 ET | Source: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
February 14, 2024 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE...
February 05, 2024 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
January 24, 2024 16:10 ET | Source: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
January 04, 2024 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
November 30, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
November 27, 2023 16:38 ET | Source: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
November 27, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
November 13, 2023 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2...